Table 1 Patient characteristics, n = 40
Aromatase inhibitor ( n = 28) | Trastuzumab ( n = 12) | |||
|---|---|---|---|---|
n (%) | Median (min, max) | n (%) | Median (min, max) | |
Age, years | 58 (35, 83) | 48 (38, 71) | ||
Postmenopausal | 21 (75%) | 9 (75%) | ||
ER positive | 28 (100%) | 6 (50%) | ||
PgR positive | 26 (93%) | 6 (50%) | ||
HER2 | ||||
Negative | 25 (89%) | 0 (0%) | ||
Positive | 0 (0%) | 12 (100%) | ||
Equivocal/not done | 3 (11%) | 0 (0%) | ||
Disease status | ||||
Newly diagnosed | 17 (61%) | 5 (42%) | ||
Recurrent | 11(39%) | 7 (58%) | ||
Disease stage | ||||
Stage I-III (newly diagnosed) | 14 (50%) | 3 (25%) | ||
Metastatic (newly diagnosed) | 3 (11%) | 2 (17%) | ||
Metastatic (recurrent, newly stage IV) | 5 (18%) | 5 (41%) | ||
Metastatic (recurrent stage IV) | 6 (21%) | 2 (17%) | ||
Histology | ||||
Ductal | 14 (50%) | 9 (75%) | ||
Lobular | 9 (32%) | 1 (8%) | ||
Ductal and lobular | 2 (7%) | 0 (0%) | ||
Unknown | 3 (11%) | 2 (17%) | ||
PET index lesion | ||||
Breast | 16 (57%) | 5 (41%) | ||
Nodal/soft tissue | 6 (21%) | 3 (25%) | ||
Bone | 1 (4%) | 2 (17%) | ||
Visceral | 5 (18%) | 2 (17%) | ||